Castle Biosciences Inc (CSTL)
Castle Biosciences - Castle BiosciencesDecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026
📉 **NEGATIVE** • Medium confidence analysis (68%) • Mild negative signal • Limited downside risk **Sentiment:** Negative (5%) **Content type:** General